|
?:abstract
|
-
Background: COVID-19 is highly contagious, potentially deadly current pandemic with no evidence-based cure or vaccines The efficacy and safety of transfusion plasma of recovered patients were tested to treat patients with severe infection Method: In this preliminary, controlled study, 30 patients were allocated to one of two groups: Standard therapy group (control, n = 15) and recovered COVID-19 plasma group (RCP, n = 15) Control group, received standard therapy alone, while patients allocated to RCP group, were given a single dose,250 ml, of plasma of recovered COVID-19 individuals, plus standard COVID-19 therapy Neutralizing antibodies and severe COVID-19 serum biomarkers e g C-reactive protein, ferritin and d-dimer were measured in all patients before and after transfusion Our primary outcome was reduction of two or more of a four-category illness-severity scale over 5 days study period: Respiratory frequency ≥24/min, blood oxygen saturation ≤ 93% on room air, partial pressure of arterial oxygen to fraction of inspired oxygen ratio 50% of both lungs Results: Plasma of recovered COVID-19 resulted in improvement of laboratory and radiological findings In RCP group, there was statistically significant improvement of clinical parameters, as well as serum ferritin, D-dimer, c-reactive protein, and the size of lung lesion compared to control group (P ≤ 0 05) COVID-19 neutralizing antibodies appeared in serum of RCV patients, but failed to show in the control group patients during 5 days study period Conclusion: Plasma of recovered COVID-19 individuals is safe and effective therapeutic modality that significantly accelerated clinical improvement in patients with severe COVID-19 infection © 2020 The Author(s) Published by Informa UK Limited, trading as Taylor & Francis Group
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}